<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929054</url>
  </required_header>
  <id_info>
    <org_study_id>Breast 2019</org_study_id>
    <nct_id>NCT04929054</nct_id>
  </id_info>
  <brief_title>PCR Based CEUS in BI RADS 4A Nodules</brief_title>
  <official_title>Principal Component Regression Based Contrast Enhanced Ultrasound Evaluating System in the Management of BI-RADS 4A Breast Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the added value of Principal Component Regression&#xD;
      (PCR) based contrast-enhanced ultrasound (CEUS) for differentiating low risk patients with&#xD;
      breast nodules categorized as 4A using the Breast Imaging Reporting and Data System&#xD;
      (BI-RADS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to investigate the added value of Principal Component Regression&#xD;
      (PCR) based contrast-enhanced ultrasound (CEUS) for differentiating low risk patients with&#xD;
      breast nodules categorized as 4A using the Breast Imaging Reporting and Data System&#xD;
      (BI-RADS). The study included patients with 4A nodules confirmed by core biopsy and/or&#xD;
      surgery. The CEUS parameters were assessed and PCR scores were calculated to evaluated the&#xD;
      added value in BI-RADS 4A nodules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>surgery or biopsy</measure>
    <time_frame>up to 3 months</time_frame>
    <description>According to the PCR result, if it's positive, the nodule category was maintained, however, if it's negative, the nodule was downgraded. all nodules were submitted to biopsy or biopsy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>PCA</condition>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>imaging</intervention_name>
    <description>ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules</description>
    <other_name>in-vitro</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pathology results of breast nodules&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with nodules which were sonographically classified as BI-RADS 4 A breast lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients with BI-RADS 4A breast lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (i) absence of a pathologic diagnosis; (ii) presence of breast nodules that were too large&#xD;
        to compare with normal parenchyma; (iii) patients with radiotherapy and chemotherapy of&#xD;
        breast cancer; and (iv) skin disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pintong Huang</last_name>
    <role>Study Chair</role>
    <affiliation>SAHZJU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SAHZJU</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

